Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Upgraded by Wall Street Zen

Zenas BioPharma (NASDAQ:ZBIO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other equities analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a report on Tuesday, February 10th. Wedbush restated an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a research note on Monday, December 22nd. Evercore assumed coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Zenas BioPharma currently has an average rating of “Moderate Buy” and an average target price of $43.14.

Zenas BioPharma Stock Performance

Shares of NASDAQ ZBIO opened at $25.88 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. Zenas BioPharma has a one year low of $6.11 and a one year high of $44.60. The business’s 50-day moving average price is $26.26 and its two-hundred day moving average price is $25.95. The company has a market capitalization of $1.39 billion, a P/E ratio of -3.66 and a beta of -1.50.

Insiders Place Their Bets

In other news, Director Hongbo Lu purchased 25,985 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was bought at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the acquisition, the director directly owned 347,968 shares of the company’s stock, valued at approximately $7,829,280. The trade was a 8.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Leon O. Moulder, Jr. purchased 57,000 shares of the stock in a transaction dated Monday, February 2nd. The stock was acquired at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the transaction, the chief executive officer owned 423,155 shares of the company’s stock, valued at $7,599,863.80. The trade was a 15.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 202,845 shares of company stock valued at $3,747,185 in the last quarter. Insiders own 16.50% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

Hedge funds have recently modified their holdings of the business. Quarry LP lifted its stake in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares during the period. Deutsche Bank AG raised its holdings in Zenas BioPharma by 4.5% in the 4th quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock valued at $464,000 after acquiring an additional 554 shares in the last quarter. CWM LLC raised its holdings in Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Zenas BioPharma by 3.9% in the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock worth $452,000 after acquiring an additional 765 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Zenas BioPharma by 5.8% in the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after acquiring an additional 818 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.